Vaccines for the 21st century : a tool for decisionmaking
著者
書誌事項
Vaccines for the 21st century : a tool for decisionmaking
National Academy Press, c2000
- : hardcover
大学図書館所蔵 全3件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes index
内容説明・目次
内容説明
Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis.
What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development.
This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines:
Lessons to be learned from the polio experience.
Scientific advances that set the stage for new vaccines.
Factors that affect how vaccines are used in the population.
Value judgments and ethical questions raised by comparison of health needs and benefits.
The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.
Table of Contents
Front Matter
Executive Summary
Introduction
Progress in Vaccine Development
Considerations of Candidate Vaccines
Overview of Analytic Approach and Results
Review of the Analytical Model
Ethical Considerations and Caveats
Observations
References
Appendix 1: Borrelia burgdorferi
Appendix 2: Chlamydia
Appendix 3: Coccidioides Immitis
Appendix 4: Cytomegalovirus
Appendix 5: Enterotoxigenic E. coli
Appendix 6: Epstein-Barr Virus
Appendix 7: Helicobacter pylori
Appendix 8: Hepatitis C
Appendix 9: Herpes Simplex Virus
Appendix 10: Histoplasma capsulatum
Appendix 11: Human Paillomavirus
Appendix 12: Influenza A and B
Appendix 13: Insulin-Dependent Diabetes Mellitus
Appendix 14: Melanoma
Appendix 15: Multiple Sclerosis
Appendix 16: Mycobacterium tuberculosis
Appendix 17: Neisseria gonnorrhea
Appendix 18: Neisseria meningitidis
Appendix 19: Parainfluenza Virus
Appendix 20: Respiratory Syncytial Virus
Appendix 21: Rheumatoid Arthritis
Appendix 22: Rotavirus
Appendix 23: Shigella
Appendix 24: Streptococcus, Group A
Appendix 25: Streptococcus, Group B
Appendix 26: Streptococcus pneumoniae
Appendix 27: Information on accessing Electronic Spreadsheets
Appendix 28: Summary of Workshops
Appendix 29: Questions Posed to Outside Experts and List of
Responders
Index
目次
- 1 Front Matter
- 2 Executive Summary
- 3 Introduction
- 4 Progress in Vaccine Development
- 5 Considerations of Candidate Vaccines
- 6 Overview of Analytic Approach and Results
- 7 Review of the Analytical Model
- 8 Ethical Considerations and Caveats
- 9 Observations
- 10 References
- 11 Appendix 1: Borrelia burgdorferi
- 12 Appendix 2: Chlamydia
- 13 Appendix 3: Coccidioides Immitis
- 14 Appendix 4: Cytomegalovirus
- 15 Appendix 5: Enterotoxigenic E. coli
- 16 Appendix 6: Epstein-Barr Virus
- 17 Appendix 7: Helicobacter pylori
- 18 Appendix 8: Hepatitis C
- 19 Appendix 9: Herpes Simplex Virus
- 20 Appendix 10: Histoplasma capsulatum
- 21 Appendix 11: Human Paillomavirus
- 22 Appendix 12: Influenza A and B
- 23 Appendix 13: Insulin-Dependent Diabetes Mellitus
- 24 Appendix 14: Melanoma
- 25 Appendix 15: Multiple Sclerosis
- 26 Appendix 16: Mycobacterium tuberculosis
- 27 Appendix 17: Neisseria gonnorrhea
- 28 Appendix 18: Neisseria meningitidis
- 29 Appendix 19: Parainfluenza Virus
- 30 Appendix 20: Respiratory Syncytial Virus
- 31 Appendix 21: Rheumatoid Arthritis
- 32 Appendix 22: Rotavirus
- 33 Appendix 23: Shigella
- 34 Appendix 24: Streptococcus, Group A
- 35 Appendix 25: Streptococcus, Group B
- 36 Appendix 26: Streptococcus pneumoniae
- 37 Appendix 27: Information on accessing Electronic Spreadsheets
- 38 Appendix 28: Summary of Workshops
- 39 Appendix 29: Questions Posed to Outside Experts and List of Responders
- 40 Index
「Nielsen BookData」 より